Back to top
more

Pfizer (PFE)

(Delayed Data from NYSE)

$29.09 USD

29.09
24,683,081

+0.12 (0.41%)

Updated Sep 27, 2024 04:02 PM ET

After-Market: $29.09 0.00 (0.00%) 7:20 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Pfizer's Pneumococcal Vaccine Gets Breakthrough Therapy Status

Pfizer's (PFE) investigational pneumococcal vaccine PF-06651600 gets Breakthrough Therapy designation from the FDA for prevention of invasive disease and pneumonia.

    Swarup Gupta headshot

    Dow 30 Stock Roundup: JPMorgan Ups Dividend, Disney's ESPN+ Hits 1M Paid Subscribers

    The index made strong gains this week as investors shrugged off trade tensions.

      Eli Lilly Prices Animal Health Unit IPO at $24 Per Share

      Lilly (LLY) prices Elanco IPO at $24 per share which is above the expected range of $20-$23 per share.

        Merck or Pfizer: Which is the Better Large-Cap Pharma Stock?

        In the Large-cap pharma sector, Merck (MRK) and Pfizer (PFE) are two of the biggest names.

          J&J Files NDA for Erdafitinib in Urothelial Cancer Indication

          Johnson & Johnson (JNJ) submits regulatory application to the FDA seeking approval of pan-FGFR inhibitor, erdafitinib, for the treatment of metastatic urothelial cancer, a type of bladder cancer.

            Is the Options Market Predicting a Spike in Pfizer (PFE) Stock?

            Investors need to pay close attention to Pfizer (PFE) stock based on the movements in the options market lately.

              Can Pfizer (PFE) Bank on Bavencio for Long-Term Growth?

              Pfizer's (PFE) latest anti-PD-L1 immunotherapy, Bavencio, is being touted as a significant long-term top-line driver for the company.

                Glaxo Seeks EU Approval for Two-Drug Regimen in First-Line HIV

                Glaxo (GSK) submits a regulatory application in the EU for a single-tablet, two-drug regimen of dolutegravir and lamivudine for the first-line treatment of HIV-1 infection.

                  Pfizer's Skin Disease Candidates Positive in Mid-Stage Study

                  Pfizer's (PFE) JAK inhibitor candidates -- PF-06651600 and PF-06700841 -- demonstrate improvements in moderate to severe alopecia areata patients in a phase II study.

                    Kinjel Shah headshot

                    Is Artificial Intelligence the Next Big Thing in Biotech?

                    Artificial intelligence can drastically reduce the time taken to develop new life-saving drugs.

                      Pfizer (PFE) Outpaces Stock Market Gains: What You Should Know

                      Pfizer (PFE) closed at $42.97 in the latest trading session, marking a +0.34% move from the prior day.

                        Pharma Stock Roundup: AZN's Leukemia Drug Wins FDA Nod, MRK's Keytruda in Focus

                        Label expansion of Merck's (MRK) Keytruda and FDA approval of AstraZeneca's (AZN) leukemia drug grab headlines this week

                          Pharma/Biotech Stocks to Watch This Prostate Cancer Month

                          Here we highlight a few companies that are focused on developing treatments for prostate cancer.

                            Swarup Gupta headshot

                            Dow 30 Stock Roundup: Apple Unveils 3 New iPhones, Boeing Clinches $2.9B Deal

                            The index chalked up gains this week amid renewed hopes of trade talks between the United States and China.

                              Pfizer's Drug Combo Betters Survival in Kidney Cancer Study

                              Pfizer's (PFE) phase III study on a combination of its cancer drugs, Bavencio and Inlyta meets primary endpoint of improving PFS in advanced kidney cancer patients with PD-L1+ tumors.

                                3 Small Biotech Stocks That Almost Doubled in Past Month

                                We take a look at three biotech stocks, prices of which have almost doubled in the past month.

                                  Exelixis' Cabometyx Recommended by NCCN for All Types of RCC

                                  Exelixis' (EXEL) lead drug, Cabometyx gets updated recommendations from the NCCN.

                                    The Zacks Analyst Blog Highlights: Novartis, AstraZeneca, Merck, Pfizer and Johnson & Johnson

                                    The Zacks Analyst Blog Highlights: Novartis, AstraZeneca, Merck, Pfizer and Johnson & Johnson

                                      Pharma Stock Roundup: NVS' Sandoz Deal, Pipeline Updates at AZN & Others in Focus

                                      Novartis (NVS) to sell parts of its Sandoz Unit. AstraZeneca (AZN), Merck (MRK), Pfizer (PFE) and others announce pipeline and regulatory updates.

                                        AstraZeneca's Asthma Drug Gets Breakthrough Therapy Status

                                        AstraZeneca (AZN) and partner Amgen's asthma candidate, tezepelumab gets Breakthrough Therapy designation from the FDA.

                                          Swarup Gupta headshot

                                          Dow 30 Stock Roundup: Coca-Cola Buys Costa, DowDuPont Earnings Impress

                                          The index remained weighed down by trade tensions during a holiday-shortened week.

                                            Pfizer's Skin Disease Drug Gets Breakthrough Therapy Status

                                            Pfizer's (PFE) investigational oral JAK3 inhibitor PF-06651600 gets Breakthrough Therapy designation from the FDA for alopecia areata.

                                              Indrajit Bandyopadhyay headshot

                                              Large Cap Pharma Stocks Staging a Comeback in Second Half

                                              Strong earnings, rising demand and successful clinical studies are paving the way for a rebound in the large-cap pharma industry in the second half.

                                                The Zacks Analyst Blog Highlights: Pfizer, Salesforce, ADP, General Motors and Southwest Airlines

                                                The Zacks Analyst Blog Highlights: Pfizer, Salesforce, ADP, General Motors and Southwest Airlines

                                                  Mark Vickery headshot

                                                  Top Analyst Reports for Pfizer, Salesforce & ADP

                                                  Today's Research Daily features new research reports on 16 major stocks, including Pfizer (PFE), Salesforce (CRM) and ADP (ADP).